Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin Hydrochloride
Phase 3ActiveDevelopment Stage
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
Mar 28, 2016 → Nov 25, 2026
About Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin Hydrochloride
Carboplatin + Cediranib Maleate + Gemcitabine + Gemcitabine Hydrochloride + Olaparib + Paclitaxel + Pegylated Liposomal Doxorubicin Hydrochloride is a phase 3 stage product being developed by AstraZeneca for Fallopian Tube Clear Cell Adenocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT02446600. Target conditions include Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02446600 | Phase 3 | Active |
Competing Products
20 competing products in Fallopian Tube Clear Cell Adenocarcinoma